The current unpredictability at the FDA is so pronounced that prominent biotech investor Peter Kolchinsky of RA Capital is now advising his portfolio companies to de-risk development by conducting early-stage clinical trials outside the United States. This marks a significant strategic shift for US-based innovators.

While speed is crucial in clinical trials, the ability to transfer data across borders is a growing pain point. Data privacy regulations, particularly in China, complicate due diligence and global collaboration, making data portability a key factor for efficiency and a significant hurdle for M&A.

China’s efficiency in early-stage clinical trials is not a threat but a global asset. It allows for faster generation of proof-of-concept data, which helps de-risk programs for all companies before they undertake expensive, global trials for FDA approval.

The updated Biosecure Act replaces a fixed list of sanctioned Chinese firms with a dynamic designation process controlled by the administration. This shifts risk for U.S. biotechs from a known quantity to an unpredictable political process, where any Chinese partner could be deemed a "company of concern" at any time.

Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

As it becomes easier and more efficient to run clinical trials in China, U.S. companies are increasingly outsourcing them. This creates a dependency where China could cut off access to trials or withhold critical new drugs, ceding the entire innovation edge.

Biotech firms are beginning to selectively disclose clinical data, citing the need to protect R&D from fast-following competitors, particularly from China. This forces investors into a difficult position: either trust management without full transparency or discount the company's value due to the opacity.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.